Abstract
Leptomeningeal metastasis (LM) is a severe complication in the natural history of malignancies that occurs in 4–15 % of patients (pts) with solid tumors. Clinical presentation, cerebrospinal fluid cytology (CSF), and gadolinium magnetic resonance imaging (gdMRI) of the brain and spine are the methods routinely used to diagnose LM. Treatment encompasses involved-field radiotherapy of bulky or symptomatic disease sites and chemotherapy; however, no standard therapy has been established yet. We collected and reviewed retrospectively the clinical, pathological, radiological findings as well as the outcomes of 50 consecutive patients with LM from solid tumors to determine whether the diagnostic modalities and therapeutic procedures affected the outcomes. The results of this study confirm the role of gdMRI in the diagnosis of LM in clinical practice and suggest that an aggressive treatment may improve survival in patients with this debilitating and increasingly frequent neurological complication.
Similar content being viewed by others
References
Chamberlain MC (1997) Carcinomatous meningitis. Arch Neurol 54:16–17
Glass JP, Melamed M, Chernik NL, Posner JB (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369–1375
Wasserstrom WR, Glass JP, Posner JB (2006) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759–772
Chamberlain MC (2006) Neoplastic meningitis. Neurologist 12:179–187
Enting RH (2005) Leptomeningeal neoplasia: epidemiology, clinical presentation, CSF analysis and diagnostic imaging. Cancer Treat Res 125:17–30
Zeiser R, Burger JA, Bley TA, Windfuhr-Blum M, Schulte-Mönting J, Behringer DM (2004) Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis—a single centre experience. Br J Haematol 124(6):762–768
Chamberlain MC, Glantz M, Groves MD, Wilson WH (2009) Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol 36(4 Suppl 2):S35–S45
Jayson GC, Howell A (1996) Carcinomatous meningitis in solid tumours. Ann Oncol 7(8):773–786
Grossman SA, Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25:103–119
Chamberlain MC (2005) Neoplastic meningitis. J Clin Oncol 23(15):3605–3612
Clarke JL, Perez HR, Jacks LM, Panageas KS, De Angelis LM (2010) Leptomeningeal metastases in the MRI era. Neurology 74:1449–1454
Rameri C, Silva de Azevedo A, Rocha Sousa Cruz M, Thome Domingos Chinen L, Verzinhasse Peres S, Aurélio Peterlevitz M et al (2011) Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. Neurooncol 104:565–572
Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, Walters BC, REchts D (1998) Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82:733–739
Chamberlain MC, Johnston SK (2009) Neoplastic meningitis: survival as a function of cerebrospinal fluid cytology. Cancer 115(9):1941–1946
Chamberlain MC, Sandy A, Press GA (1990) Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 40:435–438
Chamberlain MC, Kormanik P (1997) Prognostic significance of co-existent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol 54:1364–1368
Harstad L, Hess KR, Groves MD (2008) Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neurooncology 10:1010–1018
Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK (2008) A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neurooncology 10:208–215
Balm M, Hammack J (1996) Leptomeningeal carcinomatosis: presenting features and prognostic factors. Arch Neurol 53:626–632
Waki F, Ando M, Takashima A, Yonemori K, Nokihara H, Miyake M, Tateishi U, Tsuta K, Shimada Y, Fujiwara Y, Tamura T (2009) Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol 93(2):205–212
Herrlinger U, Förschler H, Küker W, Meyermann R, Bamberg M, Dichgans J, Weller M (2004) Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 223:167–178
Chamberlain M (2008) Neoplastic meningitis. Oncologist 13:967–977
Deisenhammer F et al (2010) European Handbook of Neurological Management, vol 1. Wiley-Blackwell, Chichester
Lin N, Dunn IF, Glantz M, Allison DL, Jensen R, Johnson MD, Friedlander RM, Kesari S (2011) Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. Neurosurgery 115(4):730–736
Conflict of interest
All authors disclose any financial and personal relationships with other people or organisations that could inappropriately influence the work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Passarin, M.G., Sava, T., Furlanetto, J. et al. Leptomeningeal metastasis from solid tumors: a diagnostic and therapeutic challenge. Neurol Sci 36, 117–123 (2015). https://doi.org/10.1007/s10072-014-1881-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-014-1881-7